

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Quantitative Structure–Cytotoxicity Relationship of Piperic Acid Amides

CHIYAKO SHIMADA¹, YOSHIHIRO UESAWA², MARIKO ISHIHARA³, HAJIME KAGAYA²,
TAISEI KANAMOTO⁴, SHIGEMI TERAOKA⁴, HIDEKI NAKASHIMA⁴, KOICHI TAKAO⁵,
TAKAKI MIYASHIRO⁵, YOSHIKI SUGITA⁵ and HIROSHI SAKAGAMI¹

Divisions of ¹Pharmacology and ³Basic Chemistry, Meikai University School of Dentistry, Sakado, Saitama, Japan;

²Department of Clinical Pharmaceutics, Meiji Pharmaceutical University, Noshio, Kiyose, Tokyo, Japan;

⁴St. Marianna University School of Medicine, Kanagawa, Japan;

⁵Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan

Reprinted from

ANTICANCER RESEARCH 34: 4877-4884 (2014)

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005

ISSN (online): 1791-7530

Editorial Board

P.A. ABRAHAMSSON, Malmö, Sweden
B. B. AGGARWAL, Houston, TX, USA
T. AKIMOTO, Kashiwa, Chiba, Japan
A. ARGIRIS, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
R. C. BAST, Houston, TX, USA
G. BAUER, Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicetre, France
Y. BECKER, Jerusalem, Israel
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
D. D. BIGNER, Durham, NC, USA
A. BÖCKING, Düsseldorf, Germany
G. BONADONNA, Milan, Italy
F. T. BOSMAN, Lausanne, Switzerland
G. BROICH, Monza, Italy
J. M. BROWN, Stanford, CA, USA
Ø. S. BRULAND, Oslo, Norway
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulu, HI, USA
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Taichung, Taiwan, ROC
E. DE CLERCQ, Leuven, Belgium
W. DE LOECKER, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMANDOPOULOS, Boston, MA, USA
D. W. FELSHER, Stanford, CA, USA
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
B. FUCHS, Zurich, Switzerland
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
J. H. GESCHWIND, Baltimore, MD, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
R. H. GOLDFARB, Saranac Lake, NY, USA
S. HAMMARSTRÖM, Umeå, Sweden
I. HELLSTRÖM, Seattle, WA, USA
L. HELSON, Quakertown, PA, USA
R. M. HOFFMAN, San Diego, CA, USA
K.-S. JEONG, Daegu, South Korea
S. C. JHANWAR, New York, NY, USA
J. V. JOHANNESSEN, Oslo, Norway
B. KAINA, Mainz, Germany
P. -L. KELLOKUMPU-LEHTINEN, Tampere, Finland
B. K. KEPPLER, Vienna, Austria
D. G. KIEBACK, Riesa (Dresden), Germany
R. KLAPDOR, Hamburg, Germany
U. R. KLEEBERG, Hamburg, Germany
P. KLEIHUES, Zürich, Switzerland
E. KLEIN, Stockholm, Sweden
S. D. KOTTARIDIS, Athens, Greece

G. R. F. KRUEGER, Köln, Germany
D. W. KUFE, Boston, MA, USA
Pat M. KUMAR, Manchester, UK
Shant KUMAR, Manchester, UK
M. KUROKI, Fukuoka, Japan
O. D. LAERUM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
L. F. LIU, Piscataway, NJ, USA
D. M. LOPEZ, Miami, FL, USA
E. LUNDGREN, Umeå, Sweden
H. T. LYNCH, Omaha, NE, USA
Y. MAEHARA, Fukuoka, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skövde, Sweden
S. MITRA, Houston, TX, USA
M. MUELLER, Heidelberg, Germany
F. M. MUGGIA, New York, NY, USA
M. J. MURPHY, Jr., Dayton, OH, USA
M. NAMIKI, Kanazawa, Ishikawa, Japan
R. NARAYANAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Houston, TX, USA
J. L. PERSSON, Malmö, Sweden
S. PESTKA, Piscataway, NJ, USA
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATSOUKAS, Norfolk, VA, USA
F. PODO, Rome, Italy
A. POLLIACK, Jerusalem, Israel
G. REBEL, Strasbourg, France
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELLI, Rome, Italy
A. SCHAUER, Göttingen, Germany
M. SCHNEIDER, Wuppertal, Germany
A. SETH, Toronto, ON, Canada
G. V. SHERBET, Newcastle-upon-Tyne, UK
G.-I. SOMA, Tokushima, Japan
G. S. STEIN, Burlington, VT, USA
T. STIGBRAND, Umeå, Sweden
T. M. THEOPHANIDES, Athens, Greece
B. TOTH, Omaha, NE, USA
P. M. UELAND, Bergen, Norway
H. VAN VLIJBERGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Duarte, CA, USA
M.R.I. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA

J. G. DELINASIOS, Athens, Greece
 Managing Editor

G. J. DELINASIOS, Athens, Greece
 Assistant Managing Editor and
 Executive Publisher

E. ILIADIS, Athens, Greece
 Production Editor

Editorial Office: International Institute of Anticancer Research, 1st km
 Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014,
 Greece. Tel / Fax: +30-22950-53389.

E-mails: Editorial Office: journals@iia-anticancer.org
 Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research.

For more information about ANTICANCER RESEARCH, IAR and the Conferences, please visit the IAR website: www.iia-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

Annual Subscription Rates 2014 per volume: Institutional subscription Euro 1,650.00 - print or online. Personal subscription Euro 780.00 - print or online. Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-33, 1981-2013) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. Cheques should be made payable to J.G. Delinasios, Executive Publisher of Anticancer Research, Athens, Greece, and should be sent to the Editorial Office.

Advertising: All correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2014 \$2.00 +0.40.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2014, International Institute of Anticancer Research
 (Dr. John G. Delinasios), All rights reserved.
 D.T.P. BY IAR
 PRINTED BY ENTYP0, ATHENS, GREECE
 PRINTED ON ACID-FREE PAPER

Quantitative Structure–Cytotoxicity Relationship of Piperic Acid Amides

CHIYAKO SHIMADA¹, YOSHIHIRO UESAWA², MARIKO ISHIHARA³, HAJIME KAGAYA²,
TAISEI KANAMOTO⁴, SHIGEMI TERAOKUBO⁴, HIDEKI NAKASHIMA⁴, KOICHI TAKAO⁵,
TAKAKI MIYASHIRO⁵, YOSHIAKI SUGITA⁵ and HIROSHI SAKAGAMI¹

Divisions of ¹Pharmacology and ³Basic Chemistry, Meikai University School of Dentistry, Sakado, Saitama, Japan;

²Department of Clinical Pharmaceutics, Meiji Pharmaceutical University, Noshio, Kiyose, Tokyo, Japan;

⁴St. Marianna University School of Medicine, Kanagawa, Japan;

⁵Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan

Abstract. *Background:* A total of 12 piperic acid amides, including piperine, were subjected to quantitative structure–activity relationship (QSAR) analysis, based on their cytotoxicity, tumor selectivity and anti-HIV activity, in order to find new biological activities. *Materials and Methods:* Cytotoxicity against four human oral squamous cell carcinoma (OSCC) cell lines and three human oral normal cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Tumor selectivity was evaluated by the ratio of the mean 50% cytotoxic concentration (CC₅₀) against normal oral cells to that against OSCC cell lines. Anti-HIV activity was evaluated by the ratio of the CC₅₀ to 50% HIV infection-cytoprotective concentration (EC₅₀). Physicochemical, structural, and quantum-chemical parameters were calculated based on the conformations optimized by LowModeMD method followed by density functional theory method. *Results:* All compounds showed low-to-moderate tumor selectivity, but no anti-HIV activity. N-Piperoyldopamine (8) which has a catechol moiety, showed the highest tumor selectivity, possibly due to its unique molecular shape and electrostatic interaction, especially its largest partial equalization of orbital electronegativities and vsurf descriptors. *Conclusion:* The present study suggests that molecular shape and ability for electrostatic interaction are useful parameters for estimating the tumor selectivity of piperic acid amides.

Piperine {1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]

piperidine)} (Compound **1** in Figure 1), along with its isomer chavicine, is an alkaloid of black pepper (1). The pungency of piperine is generated by activating the heat and acidity-sensing human transient receptor potential vanilloid receptor (TRPV1) in pain-sensing nerve cells (2). Piperine has been reported to enhance the oral absorption and hence the bioavailability of accompanying compounds, possibly by inhibiting P-glycoprotein-mediated cellular efflux and cytochrome P450 (CYP) 3A4 (3, 4). Piperine also enhanced the antimicrobial activity of rifampicin by inhibiting the multi-drug efflux pump (5). In animal studies, piperine showed anti-depression/cognitive-enhancing (6), anti-inflammatory (7) and anti-angiogenic (8) activities. Piperine also showed mild-to-moderate antibacterial activity against selected Gram-positive and Gram-negative bacteria (9).

Piperine induced apoptotic cell death in human colon (10), melanoma cells (11), and lung (12) and rectal carcinoma cell lines (13), whereas it induced autophagy in human prostate cancer cells (14), arresting the cells at G₀/G₁ phase regardless of the type of cell death (10, 11, 14). Piperine induced erythroleukemia cells to mature into monocytes/macrophages (15). On the other hand, piperine protected normal cells against apoptosis induced by cadmium (16), cisplatin (17) and glutamate (18). However, rigorous antitumor investigation with appropriate normal cells from the same tissues or same type of cells (epithelial or mesenchymal) have not yet been performed. As far as we know, only one study has reported that piperine showed no cytotoxicity against WI38 lung fibroblast as normal counterpart vs. human adenocarcinoma cell line A549 derived from lung cancer (12). There is no report on the antiviral activity of piperine.

In order to discover new biological activities of piperine, a total of 12 synthetic piperic acid amides including piperine were investigated for their cytotoxicity and anti-HIV activity, and then subjected to quantitative structure–activity relationship (QSAR) analysis.

Correspondence to: Hiroshi Sakagami, Division of Pharmacology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan. Tel: +81 492792758, Fax: +81 492855171, e-mail: sakagami@dent.meikai.ac.jp

Key Words: Piperic acid amides, QSAR analysis, cytotoxicity, tumor selectivity, anti-HIV activity.




Figure 1. Structure of piperic acid amides: piperine {1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]piperidine} (1) *N*-Piperoyl ethanolamine (2), *N*-piperoylputrescine (3), *N*-piperoylcadaverine (4), *N*-piperoylphenethylamine (5), *N*-piperoyl-3-phenylpropylamine (6), *N*-piperoyltyramine (7), *N*-piperoyldopamine (8), *N*-piperoylvanyllamine (9), *N*-piperoylserotonin (10), *N*-piperoylhistamine (11) and *N*-piperoyl-2-(2-pyridinyl)ethylamine (12).

For the cytotoxicity assay, both human normal oral cells (gingival fibroblast, HGF; periodontal ligament fibroblast, HPLF; pulp cells, HPC) and human oral squamous cell carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3, HSC-4) were used as target cells. The antitumor potential was evaluated by the tumor-selectivity index (TS), calculated by dividing the mean 50% cytotoxic concentration (CC_{50}) against normal oral cells by that against OSCC cell lines. We have recently reported that among 24 plant extracts, leaves of *Camptotheca acuminata*, a well-known source of camptothecin, had the highest TS value (88.3) among 24 plant extracts, suggesting that the TS value determined by this method seems to reflect the antitumor potential of each plant extract, although these oral normal and OSCC cell lines of oral origin are classified as different types of cells (mesenchymal or epithelial) (19).

For anti-HIV assay, mock- and HIV-infected human T-cell lymphotropic virus-I (HTLV-I)-carrying human T-cell line MT4 was used. The selectivity index (SI) was calculated by dividing the CC_{50} by the 50% HIV infection-cytoprotective concentration (EC_{50}).

Materials and Methods

Materials. The following chemicals and reagents were obtained from the indicated companies: Dulbecco's modified Eagle's medium (DMEM), from GIBCO BRL, Grand Island, NY, USA; fetal bovine serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), azidothymidine and 2',3'-dideoxycytidine from Sigma-Aldrich Inc., St. Louis, MO, USA; piperine, dimethyl sulfoxide (DMSO), dextran sulfate (molecular mass, 5 kDa) from Wako Pure Chem. Ind., Osaka, Japan; 5-fluorouracil (5-FU) from Kyowa, Tokyo, Japan; curdlan sulfate (molecular mass, 79 kDa) from Ajinomoto Co. Ltd., Tokyo, Japan. Culture plastic dishes and

plates (96-well) were purchased from Becton Dickinson Labware (Franklin Lakes, NJ, USA).

Synthesis of test compounds. *N*-Piperoyl ethanolamine (2), *N*-piperoylputrescine (3), *N*-piperoylcadaverine (4), *N*-piperoylphenethylamine (5), *N*-piperoyl-3-phenylpropylamine (6), *N*-piperoyltyramine (7), *N*-piperoyldopamine (8), *N*-piperoylvanillylamine (9), *N*-piperoylserotonin (10), *N*-piperoylhistamine (11) and *N*-piperoyl-2-(2-pyridinyl)ethylamine (12) (Figure 1) were synthesized by coupling of piperic acid with the appropriate amines by means of a modified procedure described elsewhere (20). To a mixture of piperic acid (1.0 mmol) in CH_2Cl_2 (5 ml) was added oxalyl chloride (10 mmol), and the mixture was stirred at room temperature for 3 h. The solvent and excess oxalyl chloride were then evaporated under reduced pressure. The crude acid chloride generated was dissolved in CH_2Cl_2 or dimethylformamide (DMF) (2 ml), and was added dropwise to a mixture of the appropriated amine or its hydrochloride salt (1.2 mmol) and Et₃N (8 mmol) in CH_2Cl_2 or DMF (5 ml) under ice-cooling. The reaction mixture was stirred for 5 h at room temperature. Ice-water was added to the mixture and the whole was extracted with CHCl_3 . The organic layer was dried over Na_2SO_4 and the solvent was evaporated under reduced pressure. The residue was then purified by silica gel column chromatography to give the corresponding piperic acid amide. All the conjugates were characterized by ¹H nuclear magnetic resonance (NMR) and mass spectrometry (MS) data. All compounds were dissolved in DMSO at 40 mM and stored at -20°C before use.

Cell culture. HGF, HPLF and HPC cells, established from the first premolar tooth extracted from the lower jaw of a 12-year-old girl (21), and OSCC cell lines (Ca9-22, HSC-2, HSC-3, HSC-4), purchased from Riken Cell Bank, Tsukuba, Japan were cultured at 37°C in DMEM supplemented with 10% heat-inactivated FBS, 100 units/ml, penicillin G and 100 µg/ml streptomycin sulfate under a humidified atmosphere with 5% CO₂. Cells were then harvested by treatment with 0.25% trypsin-0.025% EDTA-2Na in phosphate-buffered saline without calcium and magnesium [PSB(-)] and either subcultured or used for experiments.

Assay for cytotoxic activity. Cells were inoculated at 2.5×10³ cells/0.1 ml in a 96-microwell plate (Becton Dickinson Labware). After 48 h, the medium was removed by suction with aspirator, and replaced with 0.1 ml of fresh medium containing different concentrations of single test compounds. Control cells were treated with the same amounts of DMSO present in each diluent solution. Cells were incubated for 48 h, and the relative viable cell number was then determined by MTT method. In brief, the treated cells were incubated for another 3 h in fresh culture medium containing 0.2 mg/ml MTT. Cells were then lysed with 0.1 ml of DMSO, and the absorbance at 540 nm of the cell lysate was determined using a microplate reader (Biochromatic Labsystem, Helsinki, Finland). The CC₅₀ was determined from the dose-response curve and the mean value of CC₅₀ for each cell type was calculated from three independent experiments.

Calculation of TS. The TS was calculated by the following equation: TS=mean CC₅₀ against normal cells/mean CC₅₀ against tumor cells. Since Ca9-22 cells were derived from gingival tissue (22), the relative sensitivity of Ca9-22 and HGF was also compared.

Assay for HIV activity. HTLV-I-carrying human T-cell line MT4 cells (supplied by Dr. Naoki Yamamoto), highly sensitive to Human Immunodeficiency Virus-1 (HIV-1), were infected with HIV-1_{IIIB} at a multiplicity of infection (m.o.i.) of 0.01. HIV- and mock-infected (control) MT-4 cells were incubated for five days with different concentrations of test compounds and the relative viable cell number was determined by MTT assay. The CC₅₀ and EC₅₀ were determined from the dose-response curve for mock-infected and HIV-infected cells, respectively (23). All data represent the mean values of triplicate measurements. The anti-HIV activity was evaluated by SI (CC₅₀/EC₅₀).

Estimation of CC₅₀ values. Original data contain the sign of inequality such as ">". For the convenience of analysis, these values were changed into forms suitable for arithmetic calculation. Since ">400" is equal to "from 400 to ∞", we calculated the harmonic mean as follows: 1/[average(1/400, 1/∞)]=800. Since the CC₅₀ values had a distribution pattern close to a logarithmic normal distribution, we used the pCC₅₀ (i.e., the -log CC₅₀) for the comparison of the cytotoxicity between the compounds. The mean pCC₅₀ values for normal cells and tumor cell lines were defined as N and T, respectively (24).

Calculation of the representative value for tumor selectivity. Tumor selectivity is defined by the balance between pCC₅₀ values for normal (N) and tumor (T) cells. The difference (T-N) was used as a tumor-selectivity index only for the following QASR analyses.

Calculation of chemical descriptors. Each chemical structure was optimized by the LowModeMD method (25), a suitable search method for minimum energy conformers of flexible molecules, with Merck Molecular Force Field (MMFF94x) in Molecular Operating Environment (MOE) 2013.08 (Chemical Computing Group Inc., Quebec, Canada). Each structure was refined with density functional theory (DFT-B3LYP/6-31G**) by using Spartan10 for Windows (Wavefunction, Inc., Irvine, CA, USA) (26). During each step of the calculation, quantum chemical, molecular shape, and molecular property parameters including the partial equalization of orbital electronegativities (PEOE) and vsurf descriptors, were obtained. The parameters used were: a_{hyd} (number of hydrophobic atoms), a_{nO} (number of oxygen atoms), logP(o/w) (log of the octanol/water partition coefficient), logS (log of the aqueous solubility), PEOE_VSA_FNEG (fractional negative van der Waals surface area), PEOE_VSA_FPOS (fractional positive van der Waals surface area), PEOE_VSA_NEG (total negative van der Waals surface area), PEOE_VSA_PNEG (total negative polar van der Waals surface area), PEOE_VSA_POL (total polar van der Waals surface area), PEOE_VSA_PPOS (total positive polar van der Waals surface area), PEOE_VSA+4 (sum of v_i where q_i is in the range 0.20-0.25; v_i and q_i denote the van der Waals surface area and the partial charge of atom i, respectively), vsurf_EWmin1 (lowest hydrophilic energy 1), vsurf_HB6 (H-bond donor capacity 6), vsurf_HB7 (H-bond donor capacity 7), vsurf_IW7 (hydrophilic interaction-energy moment 7), vsurf_IW8 (hydrophilic interaction-energy moment 8), vsurf_W7 (hydrophilic volume 7).

Statistical analysis. The relation among cytotoxicity, tumor-specificity and chemical descriptors was investigated using simple regression analyses by JMP Pro version 10.0.2 (SAS Institute Inc., Cary, NC, USA). The significance level was set at p<0.05.

Table I. Cytotoxic activity of twelve piperic acid amides. Each value represents the mean \pm S.D. of triplicate assays.

Piperic acid amide	CC ₅₀ (μ M)									
	Human oral squamous cell carcinoma cell line					Human normal oral cells				
	Ca9-22	HSC-2	HSC-3	HSC-4	mean \pm S.D.	HGF	HPLF	HPC	mean \pm S.D.	TS
	(A)				(B)	(C)			(D)	(D/B) (C/A)
1	128 \pm 14	512 \pm 38	583 \pm 202	600 \pm 24	456 \pm 222	473 \pm 22	513 \pm 13	501 \pm 39	496 \pm 21	1.1 3.6
2	239 \pm 50	335 \pm 54	487 \pm 57	450 \pm 72	378 \pm 113	539 \pm 19	510 \pm 7.0	518 \pm 19	522 \pm 15	1.4 2.3
3	103 \pm 15	114 \pm 14	134 \pm 14	122 \pm 11	118 \pm 13	81 \pm 22	127 \pm 1.5	137 \pm 13	115 \pm 30	1.0 0.8
4	107 \pm 7.6	118 \pm 51	170 \pm 31	152 \pm 18	137 \pm 29	122 \pm 8.0	137 \pm 7.0	131 \pm 47	130 \pm 7.5	1.0 1.1
5	7.4 \pm 0.8	13 \pm 2.1	73 \pm 23	199 \pm 174	73 \pm 89	21 \pm 4.0	68 \pm 45	82 \pm 31	57 \pm 32	0.8 2.8
6	13 \pm 4.6	18 \pm 7.0	81 \pm 2.1	208 \pm 88	80 \pm 91	16 \pm 3.8	41 \pm 2.6	19 \pm 1.5	25 \pm 14	0.3 1.3
7	11 \pm 0.1	16 \pm 6.4	18 \pm 4.2	14 \pm 2.5	15 \pm 3.0	13 \pm 0.58	23 \pm 3.2	20 \pm 1.0	19 \pm 5.1	1.3 1.2
8	38 \pm 8.5	51 \pm 13	131 \pm 60	80 \pm 17	75 \pm 41	>800	>800	>800	>800	>10.7 >21.1
9	79 \pm 11	447 \pm 331	97 \pm 3.2	>800	>356	535 \pm 8.7	535 \pm 13	573 \pm 26	548 \pm 22	<1.5 6.8
10	33 \pm 1.2	51 \pm 13	38 \pm 7.2	58 \pm 15	45 \pm 12	41 \pm 1.7	46 \pm 2.3	75 \pm 1.2	54 \pm 18	1.2 1.2
11	455 \pm 123	696 \pm 105	>800	500 \pm 53	>613	658 \pm 36	617 \pm 33	680 \pm 41	652 \pm 32	<1.1 1.4
12	183 \pm 9.0	262 \pm 14	268 \pm 6.5	250 \pm 3.5	241 \pm 39	343 \pm 104	497 \pm 5.5	467 \pm 50	436 \pm 82	1.8 1.9
5-FU	88 \pm 11	24 \pm 7.8	38 \pm 7.6	28 \pm 4.9	45 \pm 30	>1000	>1000	>1000	>1000	>22.2 >11.4

HGF: Human gingival fibroblast; HPC, human pulp cells; HPLF, human periodontal ligament fibroblast; Ca9-22, HSC-2, HSC-3, HSC-4: human oral squamous cell carcinoma cell lines; TS: tumor-selectivity index; CC₅₀: 50% cytotoxic concentration; 5-FU: 5-fluorouracil.

Results

Cytotoxicity. Compared to the positive control, 5-FU, piperine exhibited minor tumor specificity (Table I). Among 11 other analogs, compound [8] exhibited the highest tumor specificity, whereas other compounds [2-7, 9-12] exhibited much lower tumor specificity (Table I).

Anti-HIV activity. In contrast to the higher anti-HIV activity of positive controls (dextran sulfate, curdlan sulfate, azidothymidine, 2',3'-dideoxycytidine) (SI=1789-15882), none of the piperic acid amides 1-12 were able to protect cells from cytopathic effect of HIV infection (SI<1) (Table II). Based on these data, the subsequent QSAR analysis was focused on the cytotoxicity of piperic acid amides.

Computational analysis. Cytotoxicity of piperic acid amides against tumor cells (defined by T) correlated with the partial equalization of orbital electronegativity in total negative van der Waals surface area ($r^2=0.751$, $p<0.0005$), fractional positive van der Waals surface area ($r^2=0.701$, $p<0.001$), fractional negative van der Waals surface area ($r^2=0.701$, $p<0.001$), log of the octanol/water partition coefficient ($r^2=0.492$, $p<0.05$), number of hydrophobic atoms ($r^2=0.473$, $p<0.05$) and log of the aqueous solubility ($r^2=0.432$, $p<0.05$) (Figure 2A).

On the other hand, cytotoxicity of piperic acid amides against normal cells (defined by N) was correlated with


Table II. Anti-HIV activity of piperic acid amides and chemotherapeutic agents. Each value represents the mean of triplicate determinations.

Piperic acid amides	CC ₅₀ (μ M)	EC ₅₀ (μ M)	SI
1	324	>800	<1
2	253	>800	<1
3	112	>800	<1
4	89	>800	<1
5	36	>800	<1
6	279	>800	<1
7	2	>800	<1
8	46	>800	<1
9	688	>800	<1
10	279	>800	<1
11	32	>800	<1
12	175	>800	<1
Positive controls			
Dextran sulfate (μ g/ml)	621	0.05	12363
Curdlan sulfate (μ g/ml)	>1000	0.18	5523
Azidothymidine	233	0.015	15882
2',3'-Dideoxycytidine	2145	1.2	1789

CC₅₀: 50% Cytotoxic concentration; EC₅₀: 50% effective concentration; SI: selectivity index (CC₅₀/EC₅₀).

hydrophilic interaction-energy moment 7 ($r^2=0.530$, $p<0.01$), lowest hydrophilic energy 1 ($r^2=0.491$, $p<0.05$), H-bond donor capacity 7 ($r^2=0.484$, $p<0.05$), hydrophilic volume 7 ($r^2=0.484$, $p<0.05$), H-bond donor capacity 6 ($r^2=0.476$,

A



B




Figure 2. Correlation coefficient of chemical descriptors and cytotoxicity of piperic acid amides against tumor cells (defined as T) (A) and normal cells (defined as N) (B). The mean (pCC_{50} i.e., the $-\log CC_{50}$) values for normal cells and tumor cell lines were defined as N and T, respectively. The descriptors used were: a_{hyd} (Number of hydrophobic atoms), $\log P(o/w)$ (Log of the octanol/water partition coefficient), $\log S$ (Log of the aqueous solubility), PEOE_VSA_FNEG (Fractional negative van der Waals surface area), PEOE_VSA_FPOS (Fractional positive van der Waals surface area), PEOE_VSA_NEG (Total negative van der Waals surface area), vsurf_EWmin1 (Lowest hydrophilic energy 1), vsurf_HB6 (H-bond donor capacity 6), vsurf_HB7 (H-bond donor capacity 7), vsurf_IW7 (Hydrophilic interaction-energy moment 7), vsurf_W7 (Hydrophilic volume 7).




Figure 3. Correlation coefficient of chemical descriptors and tumor specificity of piperic acid amides, defined as T-N. The descriptors used were: a_nO (Number of oxygen atoms), PEOE_VSA_PNEG (Total negative polar van der Waals surface area), PEOE_VSA_POL (Total polar van der Waals surface area), PEOE_VSA_PPOS (Total positive polar van der Waals surface area), PEOE_VSA+4 (Sum of v_i where q_i is in the range [0.20,0.25]; v_i and q_i denote the van der Waals surface area and the partial charge of atom i , respectively), vsurf_IW8 (Hydrophilic interaction-energy moment 8).

$p < 0.05$) and total positive polar van der Waals surface area ($r^2 = 0.425$, $p < 0.05$) (Figure 2B).

Tumor selectivity of piperic acid amides (defined by T-N) correlated with the vsurf descriptor in standard hydrophilic interaction-energy moment 8 (vsurf_IW)

($r^2 = 0.638$, $p < 0.005$), the partial equalization of orbital electronegativity in total polar van der Waals surface area ($r^2 = 0.609$, $p < 0.005$), sum of van der Waals surface area in atoms with the partial charge ($r^2 = 0.583$, $p < 0.005$), fractional positive van der Waals surface area ($r^2 = 0.583$, $p < 0.005$),

total negative polar van der Waals surface area ($r^2=0.519$, $p<0.01$) and number of oxygen atoms ($r^2=0.467$, $p<0.05$) (Figure 3).

Discussion

The present study demonstrated for the first time that piperine has minor antitumor potential but no anti-HIV activity, and introduction of a catechol moiety [8] significantly enhanced the tumor specificity. We found that TS values determined by two different equations (either D/B or C/A, see Table I) were considerably variable, suggesting the considerable difference in sensitivity of seven cell lines used to the 12 piperic acid amide derivatives. It is, thus, necessary that we should use more than three cell lines for both normal and tumor cell groups. Based on these experimental data, we performed the QASR analysis using the D/B value.

We could not obtain significant descriptors for T from the quantum chemical approaches. Therefore, with the assistance of descriptors calculated by MOE, a total 330 parameters were searched. We found that many PEOE descriptors, which provide information on electric charge, and vsurf descriptors, which reflect the molecular shape, explain well the cytotoxicity and tumor-selectivity of piperic acid amides. The PEOE method of calculating atomic partial charges (27) is a method in which charge is transferred between bonded atoms until equilibrium. The vsurf descriptors are similar to the VolSurf descriptors (28), and depend on the structure connectivity and conformation. We found good correlation of T with van der Waals surface area (total negative, fractional positive and negative) and hydrophobic property (Figure 2A). N correlated well with hydrophilic interaction-energy moment and energy, H-bond donor capacity and volume, and total positive polar van der Waals surface area (Figure 2B). The tumor selectivity (T-N) correlated well with van der Waals surface area (total polar, positive polar and negative polar), and number of oxygen atoms (Figure 3). Compound [8] had the highest tumor specificity, possibly due to its unique molecular shape and electrostatic interaction, especially its largest PEOE and vsurf descriptors.

Curcumin (diferuloylmethane), a natural compound extracted from *Curcuma longa* L, has been reported by many investigators to inhibit the proliferation of various tumor cells in culture, prevent carcinogenesis and inhibit the growth of implanted tumors (29). However, the evaluation system used herein for TS demonstrated that curcumin had a very narrow therapeutic window (TS=1.7) (30). Previous attempts to enhance the antitumor potential of curcumin by introducing piperic acid and glycine (31) or demethoxy, bisdemethoxy or piperoyl (32) groups were unsuccessful.

In conclusion, the present study demonstrates there are many chemical descriptors specific to cytotoxicity against normal and tumor cells, and TS. Tumor selectivity was well-correlated with molecular shape and electrostatic interaction. Multivariate statistics with these chemical descriptors may be useful for designing the most favorable compound with higher tumor selectivity.

References

- Butt MS, Pasha I, Sultan MT, Randhawa MA, Saeed F and Ahmed W: Black pepper and health claims: a comprehensive treatise. *Crit Rev Food Sci Nutr* 53(9): 875-886, 2013.
- McNamara FN, Randall A and Gunthorpe MJ: Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1)". *Br J Pharmacol* 144(6): 781-790, 2005.
- Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK and Fromm MF: Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. *J Pharmacol Exp Ther* 302(2): 645-650, 2002.
- Najar IA, Sharma SC, Singh GD, Koul S, Gupta PN, Javed S and Johri RK: Involvement of P-glycoprotein and CYP 3A4 in the enhancement of etoposide bioavailability by a piperine analogue. *Chem Biol Interact* 190(2-3): 84-90, 2011.
- Sharma S, Kumar M, Sharma S, Nargotra A, Koul S and Khan IA: Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of *Mycobacterium tuberculosis*. *J Antimicrob Chemother* 65(8): 1694-1701, 2010.
- Wattanathorna J, Chonpathompikunlerth P, Muchimapura S, Pripremc A and Tankamnerdthai O: *Food Chem Toxicol* 46(9): 3106-3110, 2008.
- Bang JS, Oh DH, Choi HM, Sur BJ, Lim SJ, Kim JY, Yang HI, Yoo MC, Hahm DH and Kim KS: Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1 β -stimulated fibroblast-like synoviocytes and in rat arthritis models. *Arthritis Res Ther* 11(2): R49, 2009. Doi: 10.1186/ar2662.
- Doucette CD, Hilchie AL, Liwski R and Hoskin DW: Piperine, a dietary phytochemical, inhibits angiogenesis. *J Nutr Biochem* 24: 231-239, 2013.
- Das B, Kundu J, Bachar SC, Uddin MA and Kundu JK: Antitumor and antibacterial activity of ethylacetate extract of *Ludwigia hyssopifolia* Linn and its active principle piperine. *Pak J Pharm Sci* 20(2): 128-131, 2007.
- Yaffe PB, Power Coombs MR, Doucette CD, Walsh M and Hoskin DW: Piperine, an alkaloid from black pepper, inhibits growth of human colon cancer cells via G1 arrest and apoptosis triggered by endoplasmic reticulum stress. *Mol Carcinog*. 2014 in press. Doi: 10.1002/mc.22176.
- Fofaria NM, Kim SH and Srivastava SK: Piperine causes G1 phase cell-cycle arrest and apoptosis in melanoma cells through checkpoint kinase-1 activation. *PLoS One* 9(5): 2014 e94298. doi:10.1371/journal.pone.0094298.
- Lin Y, Xu J, Liao H, Li L and Pan L: Piperine induces apoptosis of lung cancer A549 cells via p53-dependent mitochondrial signaling pathway. *Tumour Biol* 35(4): 3305-3310, 2014.
- Yaffe PB, Doucette CD, Walsh M and Hoskin DW: Piperine impairs cell cycle progression and causes reactive oxygen species-dependent apoptosis in rectal cancer cells. *Exp Mol Pathol* 94(1): 109-114, 2013.

- 14 Ouyang DY, Zeng LH, Pan H, Xu LH, Wang Y, Liu KP and He XH: Piperine inhibits the proliferation of human prostate cancer cells *via* induction of cell-cycle arrest and autophagy. *Food Chem Toxicol* 60: 424-430, 2013.
- 15 Song QF, Qu YC, Zheng HB, Zhang GH, Lin HG and Yang JL: Differentiation of erythroleukemia K562 cells induced by piperine. *Ai Zheng* 27(6): 571-574, 2008 (in Chinese).
- 16 Pathak N and Khandelwal S: Cytoprotective and immunomodulating properties of piperine on murine splenocytes: an *in vitro* study. *Eur J Pharmacol* 576(1-3): 160-170, 2007.
- 17 Choi BM, Kim SM, Park TK, Li G, Hong SJ, Park R, Chung HT and Kim BR: Piperine protects cisplatin-induced apoptosis *via* heme oxygenase-1 induction in auditory cells. *J Nutr Biochem* 18(9): 615-622, 2007.
- 18 Fu M, Sun ZH and Zuo HC: Neuroprotective effect of piperine on primarily cultured hippocampal neurons. *Biol Pharm Bull* 33(4): 598-603, 2010.
- 19 Suzuki R, Matsuo S, Sakagami H, Okada Y and Shirataki Y: Search for new cytotoxic crude materials against human oral squamous cell carcinoma using ¹H NMR-based metabolomics. *Anticancer Res* 34(8): 4117-4120, 2014.
- 20 Singh IP, Jain SK, Kaur A, Singh S, Kumar R, Garg P, Sharma SS and Arora SK: Synthesis and antileishmanial activity of piperoyl-amino acid conjugates. *Eur J Med Chem* 45: 3439-3445, 2010.
- 21 Kantoh K, Ono M, Nakamura Y, Nakamura Y, Hashimoto K, Sakagami H and Wakabayashi H: Hormetic and anti-radiation effects of tropolone-related compounds. *In Vivo* 24: 843-852, 2010.
- 22 Horikoshi M, Kimura Y, Nagura H, Ono T and Ito H: A new human cell line derived from human carcinoma of the gingiva. I. Its establishment and morphological studies. *Jpn J Oral Maxillofac Surg* 20: 100-106, 1974 (in Japanese).
- 23 Nakashima H, Murakami T, Yamamoto N, Sakagami H, Tanuma S, Hatano T, Yoshida T and Okuda T: Inhibition of human immunodeficiency viral replication by tannins and related compounds. *Antiviral Res* 18: 91-103, 1992.
- 24 Ohno H, Araho D, Uesawa Y, Kagaya H, Ishihara M, Sakagami H and Yamamoto M: Evaluation of cytotoxicity and tumor specificity of licorice flavonoids based on chemical structures. *Anticancer Res* 33: 3061-3068, 2013.
- 25 Labute P: LowModeMD—implicit low-mode velocity filtering applied to conformational search of macrocycles and protein loops. *J Chem Inf Model* 50: 792-800, 2010.
- 26 <http://www.computational-chemistry.co.uk/>
- 27 Gasteiger J and Marsili M: Iterative partial equalization of orbital electronegativity - A rapid access to atomic charges; *Tetrahedron* 36: 3219, 1980.
- 28 Cruciani G, Crivori P, Carrupt P-A and Testa B: Molecular Fields in Quantitative Structure-Permeation Relationships: the VolSurf Approach. *J Mol Struct (Theochem)* 503: 17-30, 2000.
- 29 Ji JL, Huang XF and Zhu HL: Curcumin and its formulations: potential anti-cancer agents. *Anticancer Agents Med Chem* 12(3): 210-218, 2012.
- 30 Sakagami H, Chowdhury SA, Suzuki F, Hashimoto K, Hatano H, Takekawa H, Ishihara M, Kikuchi H, Nishikawa H, Taniguchi S, Ito H, Hatano T, Yoshida T, Fukai T, Shirataki Y, Kawase M, Watanabe K, Mimaki Y, Itoh K, Horiuchi A, Chai W, Horiuchi A and Motohashi N: Tumor-specific cytotoxic activity of polyphenols, terpenoids, ketones and other synthetic compounds. In: *Functional Polyphenols and Carotenes with Antioxidative Action*, ed., Motohashi, Research Signpost, Lerala, India, pp. 133-176, 2005.
- 31 Singh DV, Agarwal S, Singh P, Godbole MM and Misra K: Curcumin conjugates induce apoptosis *via* a mitochondrion-dependent pathway in MCF-7 and MDA-MB-231 cell lines. *Asian Pac J Cancer Prev* 14(10): 5797-804, 2013.
- 32 Singh AK and Misra K: Human papilloma virus 16 E6 protein as a target for curcuminoids, curcumin conjugates and congeners for chemoprevention of oral and cervical cancers. *Interdiscip Sci* 5(2): 112-118, 2013.

Received May 26, 2014

Revised June 30, 2014

Accepted July 1, 2014

Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.